Key facts
- It has raised $1.4M across 1 recorded rounds; the latest was Seed Round ($1.4M) in Oct 2024.
- Notable investors include MedTech Innovator, Symbiotic Ventures, ABGD Ventures, Columbia Venture Competition.
- RadioClash has filed 1 Form D with the SEC, most recently Nov 2024 ($807K sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for RadioClash
Funding rounds
1 roundsAbout RadioClash
Developer of an interventional oncology device intended to enhance electroporation therapy for advanced cancer therapeutics. The company offers a surgical tool for combination electroporation therapy (CET) delivery, a cancer treatment that involves shocking a tumor followed by precise delivery of drugs into that tumor to increase the amount of tumor killing, and to generate an anti-tumor immune response throughout the body, providing healthcare professionals with a minimally invasive surgical instrument for liver, pancreas, and bone cancer operations.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2020
- Employees
- 6
- Website
- radioclash.co/
- Ownership
- Privately Held (backing)
RadioClash doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RadioClash shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RadioClash in its N-PORT filings yet. We sweep new filings monthly.